Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals

Pharmacological Research

Volumn 46, Issue 1, 2002, Pages 89-94

  Koks, C H W ^a   Crommentuyn, K M L ^a   Mathot R A A ^a   Mulder, J W ^a   Meenhorst, P L ^a   Beijnen, J H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Fluconazole; HIV 1 infected patients; Oropharyngeal candidiasis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCONAZOLE;

ADULT; ARTICLE; CANDIDA; CELL COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG USE; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; THRUSH; TIME; TREATMENT OUTCOME;

EID: 0036421205     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00032-4     Document Type: Article

References (20)

1. Koks CHW, Schepens MHJ, Burger DM, Underberg WJM, Mulder JW, Meenhorst PL, Beijnen JH. Drug development report (9): Fluconazole in the treatment and prophylaxis of oral candidosis in HIV-infected patients. J Drug Dev 1993; 5(4): 235-49.
2. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990; 12(Suppl 3): 334-7.
3. Ng TT, Denning DW. Fluconazole resistance in Candida in patients with AIDS - A therapeutic approach. J Infect 1993; 26: 117-25.
4. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
5. Klepser ME, Lewis RE, Pfaller MA. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options. Ann Pharmacother 1998; 32: 1353-61.
6. Bruatto M, Vidotto V, Marinuzzi G, Raiteri R, Sinicco A. Candida albicans biotypes in human immunodeficiency virus type 1-infected patients with oral candidiasis before and after antifungal therapy. J Clin Microbiol 1991; 29: 726-30.
7. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol 1994; 31: S51-5.
8. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991; 20: 332-6.
9. Budtz-Jörgensen E. Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. Acta Odontol Scand 1990; 48: 61-9.
10. Lewis MAO, Samaranyake LP, Lamey PJ. Diagnosis and treatment of oral candidosis. J Oral Maxillofac Surg 1991; 49: 996-1002.
11. Koks CHW, Meenhorst PL, Hillebrand MJX, Bult A, Beijnen JH. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother 1996; 40: 1935-7.
12. Koks CHW, Rosing H, Meenhorst PL, Bult A, Beijnen JH. High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. J Chromatogr Biomed Appl 1995; 663: 345-51.
13. Biodisk AB. Etest® Technical Guide No. 4: Antifungal Susceptibility Testing of Yeasts. Solna, Sweden: AB Biodisk, 1997.
14. Seibold M. The Etest® - An alternative to the NCCLS standard for susceptibility testing of yeasts? Mycoses 1996; 39(Suppl 2:) 44-6.
15. Beal SL, Sheiner LB. NONMEM User's Guide. San Francisco: NON-MEM Project Group, University of California at San Francisco, 1992.
16. McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection: A population analysis. Br J Clin Pharmacol 1996; 41: 291-8.
17. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Proposed Standard M27-P. Villanova, PA: National Committee for Clinical Laboratory Standards, 1992.
18. Colombo AL, Barchiesi F, McCough DA, Rinaldi MG. Comparison of Etest and National Committee for Clinical Laboratory Standards Broth Macrodilution Method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-40.
19. Sewell DL, Pfaller MA, Barry AL. Comparison of broth macrodi-lution, broth microdilution, and Etest antifungal susceptibility tests for fluconazole. J Clin Microbiol 1994; 32: 2099-102.
20. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: Technical advances and potential clinical applications. Clin Infect Dis 1997; 24: 776-84.